Conference Reports for NATAP

AASLD 60th Annual Meeting of the American Association for the Study of Liver Diseases Boston, MA, Hynes Convention Center October 30-November 3, 2009 Back

Safety, Tolerability, Pharmacokinetics and Antiviral Activity following Single- and Multiple-Dose Administration of BMS- 650032, a Novel HCV NS3 Inhibitor, in Subjects with Chronic Genotype 1 HCV Infection       Reported by Jules Levin AASLD Nov 3 2009, Boston, MA   C. Pasquinelli, T. Eley, C. Villegas, K. Sandy, E. Mathias, P. Wendelburg, S. Liao, F. McPhee, P. Scola, L. Sun, T Marbury, E Lawitz, P. Goldwater, M. Rodriguez-Torres, M. DeMicco, M. Ababa, D. Wright, M. Charlton, W. Kraft, J-C, Lopez-Talavera, DM. Grasela